Publications

Improvements in Psoriasis, Including Sexual Function and Personal Relationships, With Roflumilast Cream 0.3% and Foam 0.3%: Outcomes From the Phase 3 DERMIS-1/2 and ARRECTOR Trials

Pattern of Improvement in Scalp Versus Body Psoriasis With Roflumilast Foam 0.3%: An Analysis of the Phase 3 ARRECTOR Trial

Once-daily Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Patients Aged 2–5 Years With Diverse Skin Types: Subgroup Analysis From the Phase 3 INTEGUMENT-PED Trial

Real-World Insights Into First-Line Use of Topical Roflumilast Cream for Psoriasis

Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years

Risk of Systemic Adverse Effects from Topical and Oral Corticosteroids: Time for a Paradigm Shift?

Roflumilast Cream 0.15% Provides Improvement Across Eczema Area and Severity Index Body Regions and Clinical Signs in Patients Aged ≥6 Years With Mild-to-Moderate Atopic Dermatitis

Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial

Long-term roflumilast cream 0.15% for atopic dermatitis in patients aged 6+ years (INTEGUMENT-OLE): patient-reported outcomes

Long-term roflumilast cream 0.05% for atopic dermatitis in patients aged 2–5 years (INTEGUMENT-OLE): patient-reported outcomes